Beyond Gleevec: What's Next For Novartis Oncology?

For Novartis, the targeted chronic myeloid leukemia drug Gleevec (imatinib) has been the backbone of its oncology portfolio. The drug's launch in 2003 catapulted Novartis into a major oncology player, and with revenues for Gleevec now approaching close to $4 billion in sales annually, the drug has evolved from what was considered to be a niche treatment into Novartis' second top-selling drug